pre-update Archives

Announcement

Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development

New solution offers early-stage developers a dedicated team of experts with combined experience in end-to-end…

CertaraSeptember 19, 2024

Conference

International Congress of Parkinson’s Disease and Movement Disorders®

CertaraSeptember 18, 2024

Publication

A close examination of BCRP’s role in lactation and methods for predicting drug distribution into milk

The article, authored by Caroline Sychterz, Hong Shen, Yueping Zhang, Michael Sinz, Amin Rostami-Hodjegan, Brian…

CertaraSeptember 18, 2024

Press Release

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to…

CertaraSeptember 18, 2024

Publication

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Abstract Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually…

CertaraSeptember 18, 2024

Publication

Towards a Platform Quantitative Systems Pharmacology (QSP) Model for Preclinical to Clinical Translation of Antibody Drug Conjugates (ADCs)

Abstract A next generation multiscale quantitative systems pharmacology (QSP) model for antibody drug conjugates (ADCs)…

CertaraSeptember 18, 2024

Publication

A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers

Abstract T-cell engager (TCE) molecules activate the immune system and direct it to kill tumor…

CertaraSeptember 18, 2024

Publication

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions

Abstract Incorporating an early evaluation of dosing requirements is crucial for assessing the viability of…

CertaraSeptember 18, 2024

On-Demand Webinar

ON DEMAND [ISoP Webinar] – Physiologically Based Pharmacokinetic (PBPK) Applications in Model Informed Drug Development (MIDD) – Do You Know the Current Landscape of Regulatory Acceptance?

Model Informed Drug Development (MIDD) is a critical component in the drug development process and…

CertaraSeptember 16, 2024

Guide

A Best Practice Guide to Managing Non-CRF Data

CertaraSeptember 16, 2024

pre-update

Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development

International Congress of Parkinson’s Disease and Movement Disorders®

A close examination of BCRP’s role in lactation and methods for predicting drug distribution into milk

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Towards a Platform Quantitative Systems Pharmacology (QSP) Model for Preclinical to Clinical Translation of Antibody Drug Conjugates (ADCs)

A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions

ON DEMAND [ISoP Webinar] – Physiologically Based Pharmacokinetic (PBPK) Applications in Model Informed Drug Development (MIDD) – Do You Know the Current Landscape of Regulatory Acceptance?

A Best Practice Guide to Managing Non-CRF Data

Newsletter sign up

Quick links

Solutions

Contact